NDANASALSPRAY
Approved
Jan 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
TOSYMRA (sumatriptan) by GSK is serotonin 1b receptor agonists [moa]. Approved for migraine. First approved in 2019.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TOSYMRA (sumatriptan) is a nasal spray formulation of the triptan class serotonin 1b/1d receptor agonist approved for acute treatment of migraine, cluster headache, and post-traumatic headache. It works by constricting blood vessels and reducing substances in the body that can trigger headaches, nausea, sensitivity to light and sound, and other migraine symptoms. The nasal delivery route offers rapid onset and non-oral convenience for acute migraine sufferers.
$0.492MPart D
Peak5.2 years to LOEProduct is in peak commercial phase with modest Part D penetration; brand team size likely stable or moderately sized.
Mechanism of Action
Serotonin 1b Receptor Agonists
Pharmacologic Class:
Serotonin-1b and Serotonin-1d Receptor Agonist
Indications (1)
Clinical Trials (20)
A STUDY TO EVALUATE THE EFFECT OF PF-06651600 ON PHARMACOKINETICS OF SINGLE DOSE SUMATRIPTAN IN HEALTHY PARTICIPANTS.
Started Jun 2020
10 enrolled
Healthy Volunteers
Sofusa System With Sumatriptan (KC5010) Phase 1 Dose Escalation Safety and PK Study (KCC-SMT-002)
Started Jan 2018
19 enrolled
Migraine Disorders
A Study of Lasmiditan When Given With Sumatriptan in Healthy Participants
Started Oct 2017
40 enrolled
Healthy
Low-Dose Naltrexone and Acetaminophen Combination and Sumatriptan in the Acute Treatment of Migraine With Nausea
Started Jun 2017
36 enrolled
Migraine With and Without Aura
Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants
Started Mar 2017
42 enrolled
Migraine
Worked on TOSYMRA at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.